Filtered By:
Drug: Methylphenidate

This page shows you your search results in order of date.

Order by Relevance | Date

Total 25 results found since Jan 2013.

Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
ConclusionOur findings suggest little to no increased risk of cardiovascular and cerebrovascular events in patients treated with LDX compared with patients previously treated with other ADHD medications.
Source: Neurology and Therapy - October 23, 2022 Category: Neurology Source Type: research

Stimulants May Pose Short-Term Cardiovascular Risks in Older Adults
Older adults prescribed stimulant medications appear to be at an elevated risk of cardiovascular problems in the first 30 days after beginning the treatment, according to astudy published today inJAMA Network Open. However, these risks decrease over time, with no evidence of increased cardiovascular risk at six months and one year after initiating treatment.“Although stimulants are most commonly used among children and youth for the treatment of attention-deficit/hyperactivity disorder (ADHD), an increase in stimulant use among older adults in recent years has been observed,” wrote Mina Tadrous, PharmD., Ph.D., of the ...
Source: Psychiatr News - October 25, 2021 Category: Psychiatry Tags: cardiovascular problems heart attack JAMA Network Open off-label use older adults stimulants stroke transient ischemic attack ventricular arrhythmia Source Type: research

A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.
CONCLUSIONS: The pharmacologic agent with the most supporting literature is amantadine used for cognitive improvement after TBI. Other neurostimulants with positive, despite more limited, evidence include methylphenidate, modafinil, levodopa, and citalopram. Caution is warranted with other neurostimulants given higher rates of adverse effects or lack of benefit observed in clinical trials. PMID: 33435717 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 12, 2021 Category: Drugs & Pharmacology Authors: Kakehi S, Tompkins DM Tags: Ann Pharmacother Source Type: research

Takotsubo cardiomyopathy associated with serotonin syndrome in a patient with stroke: A case report
We describe a patient with stroke who presented with TC caused by serotonin syndrome (SS) following the administration of serotonergic and dopaminergic agents. Patient concerns: A 55-year-old man with stroke was administered venlafaxine, tianeptine, ropinirole, carbidopa/levodopa, bromocriptine, and methylphenidate during rehabilitation. The patient presented with clinical features of SS (mental confusion, agitation, hyperhidrosis, chills, rigidity, and tachycardia), which persisted over 24 hours. The day after his SS symptoms disappeared, the patient's blood pressure decreased, and he developed tachycardia. Diagnose...
Source: Medicine - March 1, 2019 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research

Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis
AbstractThis meta-analysis was conducted to evaluate the association between Attention deficit hyperactivity disorder (ADHD) medications and risk of sudden death/arrhythmia, stroke, myocardial infarction as well as all-cause death. We searched PubMed, Web of Science and China National Knowledge Infrastructure from 1950 to May 2018. All observational studies that the exposure of interest was ADHD medications, the outcome of interest was sudden death/arrhythmia, stroke, myocardial infarction as well as all-cause death, and the study reported relative risks (RRs) with 95% confidence intervals (95% CIs) were included. Pooled R...
Source: European Child and Adolescent Psychiatry - August 24, 2018 Category: Psychiatry Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Effects of monoaminergic drugs on training-induced motor cortex plasticity in older adults.
Abstract Primary motor cortex (M1) plasticity is involved in motor learning and stroke motor recovery, and enhanced by increasing monoaminergic transmission. Age impacts these processes but there is a paucity of systematic studies on the effects of monoaminergic drugs in older adults. Here, in ten older adults (age 61+ 4 years, 4 males), we determine the effects of a single oral dose of carbidopa/levodopa (DOPA), d-amphetamine (AMPH), methylphenidate (MEPH) and placebo (PLAC) on M1 excitability and motor training-induced M1 plasticity. M1 plasticity is defined as training related long lasting changes in M1 excitab...
Source: Brain Research - June 17, 2017 Category: Neurology Authors: Kesar TM, Belagaje SR, Pergami P, Haut MW, Hobbs G, Buetefisch CM Tags: Brain Res Source Type: research

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine
ConclusionsStatistically significant pre –post increases of SBP, DBP and HR were associated with AMP and ATX treatment in children and adolescents with ADHD, while MPH treatment had a statistically significant effect only on SBP in these patients. These increases may be clinically significant for a significant minority of individuals tha t experience larger increases. Since increased BP and HR in general are considered risk factors for cardiovascular morbidity and mortality during adult life, paediatric patients using ADHD medication should be monitored closely and regularly for HR and BP.
Source: CNS Drugs - February 23, 2017 Category: Neurology Source Type: research

Update on pharmacotherapy for stroke and traumatic brain injury recovery during rehabilitation
This article evaluates whether specific drugs are able to facilitate motor recovery after stroke or improve the level of consciousness, cognitive, or behavioral symptoms after traumatic brain injury. Recent findings: After stroke, serotonin reuptake inhibitors can enhance restitution of motor functions in depressed as well as in nondepressed patients. Erythropoietin and progesterone administered within hours after moderate to severe traumatic brain injury failed to improve the outcome. A single dose of zolpidem can transiently improve the level of consciousness in patients with vegetative state or minimally conscious stat...
Source: Current Opinion in Neurology - November 8, 2016 Category: Neurology Tags: TRAUMA AND REHABILITATION: Edited by Bruce H. Dobkin Source Type: research

Ritalin Could Trigger Heart Problems In Children
Ritalin and similar forms of ADHD medication may trigger abnormal heart rhythms and increase heart attack risk in some children soon after they start taking the drug, according to a new study.  This connection was especially true for children who were born with heart disease. According to the study, published in the British medical journal BMJ, kids had an increased risk of heart attack between eight and 56 days after starting methylphenidate, a stimulant most commonly sold as Ritalin, although this heightened risk didn’t reach statistical significance. The researchers could find no evidence of a heightened...
Source: Science - The Huffington Post - June 8, 2016 Category: Science Source Type: news

Methylphenidate May Increase Risk for Arrhythmias, Myocardial Infarction In Some Youth
Findings from a study published in BMJ Open Access shows that some children and adolescents who are receiving methylphenidate for treatment of attention-deficit/hyperactivity disorder (ADHD) may be at increased risk for certain adverse cardiovascular events. "Drugs to treat ADHD have been shown to be efficacious in reducing symptoms of impulsivity and hyperactivity in children,” the study authors wrote, "but concerns have been expressed about possible adverse cardiovascular events with the first-line treatment, methylphenidate."To determine whether an association exists between methylphenidate and adverse cardiovascular ...
Source: Psychiatr News - June 3, 2016 Category: Psychiatry Tags: ADHD cardiovascular risk methylphenidate youth Source Type: research

Probable Nootropic-induced Psychiatric Adverse Effects: A Series of Four Cases
Conclusion Healthcare providers in general, and specifically those in the mental health and substance abuse fields, should keep in mind that nootropic use is an under recognized and evolving problem. Nootropic use should be considered in cases where there are sudden or unexplained exacerbations of psychiatric symptoms in patients who have been stable and medication adherent. It is also important to remember that most nootropics are not detected on standard drug toxicology screening tests. We have very little clinical information on how nootropics may interact with psychotropics (or other medications) and potentially cause ...
Source: Innovations in Clinical Neuroscience - December 1, 2015 Category: Neuroscience Authors: ICN Online Editor Tags: Case Series and Literature Review Current Issue Mental Disorders Psychiatry Psychopharmacology Substance Use Disorders Ampakines Armodafinil brain enhancer Cerebrolysin Citicoline cognitive enhancer homeopathic medicine natural r Source Type: research

Home computerised cognitive testing for tbi is feasible and popular
Serial neuropsychological testing potentially provides a powerful tool for tracking disease progress and identifying treatment response. Formal neuropsychometric assessment by a clinical psychologist is ideal but impractical for regular testing. Remote computerised assessment resolves this difficulty by allowing frequent home assessment, but is potentially limited by patient compliance and practise effects. We study the feasibility of this approach in an on-going clinical trial investigating the effects of methylphenidate on cognition after traumatic brain injury (TBI): Dopamine's Role in Enhancing Attention and Memory (DR...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 14, 2015 Category: Neurosurgery Authors: Jenkins, P., Fleminger, J., De-Simoni, S., Jolly, A., Gorgoraptis, N., Hampshire, A., Sharp, D. Tags: Neurological injury, Stroke, Trauma CNS / PNS, Trauma, Injury Thur 21, Parallel session 5: Therapeutics Source Type: research

The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke.
CONCLUSION: Our systematic review demonstrates an evolving evidence base to suggest some benefits in agitation and aggression, mood and attentional deficits. However, there are key limitations of the studies undertaken to date involving small numbers of participants, heterogeneous outcome measures, and variable study designs. There is a need for on-going large prospective double-blind RCTs in these medications using standardised criteria and outcomes to fully understand their effectiveness in this patient group. PMID: 25850757 [PubMed - as supplied by publisher]
Source: Acta Neuropsychiatrica - April 11, 2015 Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research